Candida antigen in the treatment of basal cell carcinoma

Dermatologic Surgery

Volumn 31, Issue 1, 2005, Pages 16-18

  Aftergut, Kent ^a,b   Curry, Mary ^a   Cohen, Jack ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANDIDA ANTIGEN; CANDIN; PLACEBO; SODIUM CHLORIDE;

ARTICLE; BASAL CELL CARCINOMA; BLEEDING; CANCER PAIN; CLEARANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FISHER EXACT TEST; FLU LIKE SYNDROME; HUMAN; IMMUNOTHERAPY; INJECTION PAIN; OPEN STUDY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN ULCER;

EID: 11844275239     PISSN: 10760512     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042728-200501000-00003     Document Type: Article

References (15)

1. Miller SJ. Etiology and pathogenesis of basal cell carcinoma. Clin Dermatol 1995;13:527-36.
2. Preston DS, Stern RS. Nonmelanoma cancers of the skin. N Engl J Med 1992;327:1649-62.
3. Gaspari AA. Immune response modifiers: an emerging therapeutic option for basal cell carcinoma. Dermatol Times Suppl 2003;24:11-3.
4. Otley CC, Coldtron BM, Goldman GD. Decreased skin cancer after cessation of therapy with transplant-associated immunosuppressants. Arch Dermatol 2001;137:459-63.
5. Bergstresser PR. Ultraviolet immunosuppression. Prog Dermatol 2000;34:1-2.
6. Kim J, Modlin RL, Moy RL, et al. IL-10 production for evading the local T cell immune response. J Immunol 1995;155:2240-7.
7. Ikec D, Padovan IN, Pipic N, et al. Interferon therapy for basal cell carcinoma and squamous cell carcinoma. Int J Clin Pharmacol 1991;29:342-6.
8. Kaplan B, Moy RL. Effect of perilsional injection of PEG-IL-2 on basal cell carcinoma. Dermatol Surg 2000;26:1037-40.
9. Tyring SK, Arany II, Stanley MA, et al. Mechanism of action of imiquimod 5% cream in the treatment of anogenital warts. Prim Care Update Ob Gyns 1998;5:151-2.
10. Helm F, Klein E. Effect of allergic contact dermatitis on basal cell epitheliomas. Arch Dermatol 1965;91:142.
11. Holtermann O, Papermaster B, Rosner D, et al. Regression of cutaneous neoplasms following delayed type hypersensitivity challenge reaction to microbial antigens or lymphokines. J Med Exp Clin 1975;6:157-68.
12. Stjernsward J, Levin A. Delayed hypersensitivity-induced regression of human neoplasm. Cancer 1971;28:628.
13. Zbar B, Bernstein I, Rapp H. Suppression of tumor growth at the site of infection with living bacillus Calmette-Guérin. J Natl Can Inst 1971;46:831.
14. Klein E, Holtermann O, Djerassi I. Immunotherapy for accessible tumors utilizing delayed hypersensitivity reactions and separated components of the immune system. Med Clin North Am 1976;60:389-418.
15. Holtermann O, Papermaster B, Klein E. Regression of cutaneous neoplasms following delayed-type hypersensitivity challenge reactions to microbial antigens or lymphokines. J Med 1975;6:157-68.